Here are a few analogies for Praxis Precision Medicines:

1. An early-stage Biogen, but focused on a broader spectrum of brain disorders like depression, epilepsy, and tremor.
2. Imagine the neuroscience R&D division of a major pharmaceutical company like Eli Lilly or Pfizer, but spun out as a dedicated, independent clinical-stage biotech.

• PRAX-114: A GABAA receptor positive allosteric modulator in development for major depressive disorder and perimenopausal depression.
• PRAX-944: A selective small molecule inhibitor of T-type calcium channels being developed for essential tremor.
• PRAX-562: A persistent sodium current blocker in development to treat severe pediatric epilepsy and adult cephalgia.
• PRAX-222: An antisense oligonucleotide (ASO) therapy for patients with gain-of-function (GOF) SCN2A epilepsy.
• KCNT1 program: A therapeutic development program aimed at treating KCNT1 gain-of-function (GOF) epilepsy.

Praxis Precision Medicines (PRAX) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. As a clinical-stage company, its product candidates are currently in various phases of clinical trials and are not yet approved for commercial sale. Therefore, Praxis Precision Medicines does not currently have major customers that purchase its products, whether other companies or individuals, in the traditional sense of commercial sales.

• Ionis Pharmaceuticals, Inc. (IONS)

Marcio Souza, President and Chief Executive Officer

Marcio Souza has served as the President, Chief Executive Officer, and a director of Praxis Precision Medicines since April 2020. Prior to joining Praxis, Mr. Souza was the Chief Operating Officer at PTC Therapeutics, Inc. from May 2017 to April 2020, and served as its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. He previously held positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc., and Sanofi Genzyme Corporation. Mr. Souza has also served on the board of directors for other companies, including Aeglea BioTherapeutics, Inc. since June 2021 and Clearpoint Neuro, Inc. from May 2019 to May 2020. Praxis Precision Medicines itself received significant private equity funding during its early stages.

Tim Kelly, Chief Financial Officer

Tim Kelly has served as the Chief Financial Officer of Praxis Precision Medicines since May 2021. Before joining Praxis, Mr. Kelly was the Chief Financial Officer and Head of Corporate Management at Foundation Medicine from January 2019 to April 2021, where he oversaw finance and corporate management teams. Prior to that, he spent more than 15 years in various finance leadership roles within the Roche Group, including serving as the finance and corporate services director for Roche Pharma in the UK and head of group strategic planning for the Roche Group in Switzerland.

Steven Petrou, Ph.D., Co-Founder, President of Research & Development

Dr. Steven Petrou is a Co-Founder of Praxis Precision Medicines and serves as its President of Research & Development, a role he was promoted to in January 2026. He was previously the Chief Scientific Officer. Dr. Petrou is recognized as a leader in ion channel disease biology and precision medicine, and has been a key architect of Praxis's scientific foundation and development strategy. He was formerly the institute director of The Florey Institute of Neuroscience and Mental Health.

Megan Sniecinski, Chief Operating Officer

Megan Sniecinski was promoted to Chief Operating Officer in January 2026. In this role, she is responsible for operationalizing the company's growth strategy, overseeing enterprise execution, program strategy and operations, and corporate development. Previously, she served as Chief Business Officer at Praxis. Ms. Sniecinski's background includes serving as Chief Business Officer at BioCryst Pharmaceuticals and Senior Vice President of Business Operations and Program Management at PTC Therapeutics. She also spent over a decade at Merck in various operational and strategic roles.

Alyssa Wyant, Chief Regulatory & Quality Officer

Alyssa Wyant holds the position of Chief Regulatory & Quality Officer at Praxis Precision Medicines. She was promoted to this role in December 2021, having made significant contributions to the company's accomplishments.

1. Clinical Trial Failure and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Praxis Precision Medicines' success is almost entirely dependent on its product candidates successfully completing rigorous and lengthy clinical trials, demonstrating efficacy and safety, and ultimately receiving regulatory approval. The company's lead candidates, PRAX-114 and PRAX-944, are in Phase IIa clinical trials, and PRAX-562 is in Phase I. These early-stage trials have a high rate of failure, and there is no guarantee that any of their product candidates will advance to later stages, achieve regulatory approval, or become commercially viable.
2. Dependence on a Limited Number of Product Candidates and Challenges of CNS Drug Development: The company's pipeline consists of a limited number of product candidates, with the most advanced being in Phase IIa. The failure of one or more of these key candidates, particularly PRAX-114 or PRAX-944, could significantly and adversely impact the company's future prospects. Furthermore, developing therapies for central nervous system (CNS) disorders is inherently challenging, often associated with high failure rates and extended development timelines due to the complexity of the brain and the difficulty in achieving therapeutic targets effectively and safely.

Praxis Precision Medicines (symbol: PRAX) is developing therapies for several central nervous system disorders. The addressable markets for their main product candidates are as follows:

• PRAX-114 (Major Depressive Disorder and Perimenopausal Depression)

  • For **Major Depressive Disorder**, the global market size was estimated to be between USD 6.26 billion in 2025 and USD 8.18 billion in 2025, with projections to reach approximately USD 7.49 billion by 2030 to USD 14.57 billion by 2033. The market across eight major markets (US, France, Germany, Italy, Spain, UK, Japan, and Canada) is projected to reach USD 9.6 billion by 2029. In 2023, the market size in the seven major markets (US, EU4 countries, and Japan) was approximately USD 7,165 million, with the United States accounting for approximately USD 5,600 million. North America is a significant market for Major Depressive Disorder treatment.

  • For **Perimenopausal Depression**, a specific standalone market size for treatments directly addressing "perimenopausal depression" is not readily available in the provided search results. However, perimenopausal depression is a component of the broader menopause market. The global menopause market was valued at approximately USD 17.7 billion to USD 19.72 billion in 2024, with projections to reach between USD 24.35 billion by 2030 and USD 33.32 billion by 2033. The menopause market in the seven major markets (US, EU4 countries, UK, and Japan) was estimated at nearly USD 10,970 million in 2023. The North America menopausal disorder treatment market was valued at USD 5,957.4 million in 2022 and is expected to grow to USD 10,704.2 million by 2030.

• PRAX-944 (Essential Tremor)

  • The global essential tremor treatment market size was valued at approximately USD 129.75 million to USD 166.06 million in 2024, with projections to reach between USD 211.53 million by 2032 and USD 302.86 million by 2035. In 2024, the seven major essential tremor markets reached a value of USD 134.0 million and are expected to reach USD 298.6 million by 2035. North America leads this market, accounting for a significant share of global demand. The United States alone is estimated to have 7 to 10 million individuals affected by essential tremor.

• PRAX-562 (Severe Pediatric Epilepsy and Adult Cephalgia)

  • For **Severe Pediatric Epilepsy**, the global pediatric epilepsy therapeutics market size was valued between USD 2.1 billion and USD 12.1 billion in 2024, with projections to reach between USD 3.9 billion by 2032 and USD 14.7 billion by 2030. The global anti-epileptic drugs for pediatrics market was valued at approximately USD 1.1 billion in 2024 to USD 1.50 billion in 2025, expected to reach USD 1.5 billion by 2030 to USD 3.25 billion by 2035. The U.S. pediatric epilepsy treatment drugs market had a revenue of USD 844.4 million in 2024. North America is the largest market for pediatric epilepsy therapeutics.
  • For **Adult Cephalgia** (a general term for headache), the global headache disorders market size was USD 3.99 billion in 2022 and is expected to grow up to USD 6.55 billion by 2030. Specifically for migraine, the total market size in the seven major markets was approximately USD 10,880 million in 2023, with the US market at approximately USD 6,790 million in the same year. For cluster headache, a type of cephalgia, the global market size was valued at approximately USD 401.82 million in 2024 to USD 449.3 million in 2025, projected to reach between USD 595 million by 2033 and USD 694.0 million by 2032. North America is a leading region in the cluster headache market.

• PRAX-222 (SCN2A Epilepsy) and KCNT1 program (KCNT1 GOF Epilepsy)

  • Specific addressable market sizes for highly rare genetic epilepsies like SCN2A Epilepsy and KCNT1 GOF Epilepsy are not explicitly available as standalone figures in the provided market reports. These conditions would typically fall under the broader categories of rare epilepsies or severe pediatric epilepsies, for which market sizes are provided above.

Praxis Precision Medicines (PRAX) is poised for significant revenue growth over the next 2-3 years, primarily driven by the anticipated commercialization of its late-stage pipeline assets and potential milestone payments from strategic collaborations.

Here are the key expected drivers of future revenue growth:

1. Commercialization of Ulixacaltamide for Essential Tremor: Praxis submitted a New Drug Application (NDA) for ulixacaltamide in essential tremor by mid-February 2026. This product candidate has received Breakthrough Therapy Designation from the FDA and represents the first successful Phase 3 program for a pharmacological treatment of essential tremor. Ulixacaltamide is targeting a substantial market with approximately 2 million addressable essential tremor patients in the U.S., and management anticipates peak revenue estimates exceeding $10 billion. The company is actively building its commercial infrastructure, hiring leadership, and accelerating disease awareness in preparation for a potential launch.
2. Commercialization of Relutrigine for SCN2A/8A-DEEs: The company also submitted an NDA for relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) by mid-February 2026, also holding Breakthrough Therapy Designation. The EMBOLD study demonstrated rapid and durable seizure control in patients with these ultra-rare DEEs. Praxis expects to submit a supplemental New Drug Application (sNDA) by 2027, based on the EMERALD trial, to expand the indication for relutrigine to a broader range of developmental and epileptic encephalopathies. This asset addresses a high unmet medical need and has potential for blockbuster revenue.
3. Potential Approval and Launch of Elsunersen (PRAX-222) for SCN2A-DEE: Elsunersen (PRAX-222), an antisense oligonucleotide (ASO), is in a registrational trial (EMBRAVE3) for early-seizure-onset SCN2A-DEE, with patient enrollment anticipated to begin by mid-2025. Topline results from an ongoing part of the EMBRAVE study are expected in the first half of 2026. Elsunersen has been granted rare pediatric drug designation, which could qualify Praxis for a pediatric review voucher upon approval. Praxis believes elsunersen has the potential to generate over $1 billion in annual revenue once approved.
4. Milestone Payments and Royalties from KCNT1 Program: Praxis has a collaboration agreement with UCB for its KCNT1 program. UCB exercised its option to in-license global development and commercialization rights for a KCNT1 small molecule development candidate. As a result, Praxis has received an option exercise fee and is eligible for future success-based development and commercialization milestone payments, totaling up to approximately $100 million, in addition to tiered royalties on net sales of any resulting products from the collaboration. These payments will contribute to the company's revenue streams as the program progresses.

Share Issuance

• Praxis Precision Medicines completed a public offering in 2025, raising approximately $567.1 million through the issuance of common stock and pre-funded warrants.
• In January 2026, the company executed another public offering that generated approximately $621.2 million.
• In October 2025, a public offering was priced to raise around $525 million through common stock and pre-funded warrants.

Inbound Investments

• Praxis Precision Medicines launched in May 2020 with $100 million in financing supported by Blackstone Life Sciences and Novo Holdings.
• As of December 31, 2025, the company reported $926.1 million in cash, cash equivalents, and marketable securities.
• Perceptive Advisors significantly increased its stake in Praxis by 431,432 shares in Q4 2025, with an estimated transaction value of $80.34 million.

Capital Expenditures

• Praxis Precision Medicines reported capital expenditures of $0.06 million in 2024.
• For fiscal year 2025, capital expenditures were $56,000, primarily focused on funding long-term assets and infrastructure.
• Significant capital is directed towards research and development, with expenses reaching $267.1 million in fiscal year 2025, a 75.3% increase from the prior year, primarily for its Cerebrum™ and Solidus™ platforms.